Next Article in Journal
Development and Assessment of a Diagnostic DNA Oligonucleotide Microarray for Detection and Typing of Meningitis-Associated Bacterial Species
Previous Article in Journal
Molecular Lesions of Insulator CTCF and Its Paralogue CTCFL (BORIS) in Cancer: An Analysis from Published Genomic Studies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
High-Throughput
Volume 7
Issue 4
10.3390/ht7040031
high-throughput-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Please note that, as of 21 September 2020, High-Throughput has been renamed to BioTech and is now published here.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Impact of Genomics on Clarifying the Evolutionary Relationships amongst Mycobacteria: Identification of Molecular Signatures Specific for the Tuberculosis-Complex of Bacteria with Potential Applications for Novel Diagnostics and Therapeutics

by
Radhey S. Gupta
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada
High-Throughput 2018, 7(4), 31; https://doi.org/10.3390/ht7040031
Submission received: 6 August 2018 / Revised: 25 September 2018 / Accepted: 27 September 2018 / Published: 2 October 2018
Browse Figures
Versions Notes

Abstract

:
An alarming increase in tuberculosis (TB) caused by drug-resistant strains of Mycobacterium tuberculosis has created an urgent need for new antituberculosis drugs acting via novel mechanisms. Phylogenomic and comparative genomic analyses reviewed here reveal that the TB causing bacteria comprise a small group of organisms differing from all other mycobacteria in numerous regards. Comprehensive analyses of protein sequences from mycobacterial genomes have identified 63 conserved signature inserts and deletions (indels) (CSIs) in important proteins that are distinctive characteristics of the TB-complex of bacteria. The identified CSIs provide potential means for development of novel diagnostics as well as therapeutics for the TB-complex of bacteria based on four key observations: (i) The CSIs exhibit a high degree of exclusivity towards the TB-complex of bacteria; (ii) Earlier work on CSIs provide evidence that they play important/essential functions in the organisms for which they exhibit specificity; (iii) CSIs are located in surface-exposed loops of the proteins implicated in mediating novel interactions; (iv) Homologs of the CSIs containing proteins, or the CSIs in such homologs, are generally not found in humans. Based on these characteristics, it is hypothesized that the high-throughput virtual screening for compounds binding specifically to the CSIs (or CSI containing regions) and thereby inhibiting the cellular functions of the CSIs could lead to the discovery of a novel class of drugs specifically targeting the TB-complex of organisms.

Graphical Abstract

1. Introduction

Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, is the leading cause of death from an infectious agent worldwide [1]. In 2016, an estimated 10.4 million people were infected with TB, leading to the deaths of 1.7 million people [1]. Additionally, a third of the global population is latently infected with M. tuberculosis and is at risk of developing the active disease. These factors have led to TB being declared as a global health emergency by the World Health Organization [1]. Alarmingly, an increasing number of new cases of TB are due to multidrug-resistant (MDR), or extensively drug-resistant (XDR), strains of M. tuberculosis, which are not responsive to different first-line TB drugs as well as many other drugs used for the treatment of TB [1,2,3]. This is leading towards a crisis situation in the treatment and/or management of TB, where unless new drugs that are effective against the resistant strains of TB are developed [4,5,6,7], it will become very difficult to treat and control the spread of drug-resistant TB in the population. Thus, there is an urgent need for the development of new antimycobacterial drugs, acting via novel mechanisms, which are effective in killing both sensitive as well as resistant strains of M. tuberculosis. The availability of genome sequences for M. tuberculosis and other mycobacteria has provided a great impetus in the search for new drug targets for development of novel therapeutics for treatment of TB [5,6,7,8,9]. However, thus far the use of genomics for the identification of novel drug targets and treatment of TB has been explored to only a limited extent [5,6,7,8,9] and innovative comparative genomic approaches hold much promise of identifying many novel drug targets that can be exploited for the development of a new arsenal of antituberculosis drugs.
For identification of potential drug targets for treatment of tuberculosis, it is important to first understand how the TB causing bacteria are related to, or differ from, other bacteria. In this context, it should be noted that M. tuberculosis is a member of the genus Mycobacterium, which until recently constituted the sole genus within the family Mycobacteriaceae, containing >188 different named species [10,11]. While a limited number of species from the genus Mycobacterium are important human and animal pathogens (e.g., M. tuberculosis, Mycobacterium leprae and Mycobacterium bovis) [10], a vast majority of the species within this genus are nonpathogenic and are found in diverse environments including water bodies, soil, and metalworking fluids [12,13,14,15]. Until recently, members of the genus Mycobacterium (family Mycobacteriaceae), which are a part of the phylum Actinobacteria [16], were distinguished from other Actinobacteria and other phyla of bacteria primarily on the basis of their distinct branching in phylogenetic trees based on 16S rRNA or other genes/proteins sequences [10,13,17]. Apart from their branching pattern in phylogenetic trees, no reliable characteristic was known that was specific for either all mycobacteria, or different main groups present within this genus/family, which can reliably differentiate the important groups of pathogenic species from nonpathogenic mycobacteria [10,13,17].
Genome sequences are now available for >150 of the 188 known mycobacterial species providing an excellent coverage of the genetic diversity existing within the genus Mycobacterium and providing a comprehensive resource for robustly elucidating the evolutionary relationships among mycobacterial species using different genome-scale approaches [18,19,20]. Additionally, comparative analyses of genome sequences by innovative approaches provide a rich resource for the identification of novel molecular characteristics that are specifically shared by either all mycobacteria or different major groups within mycobacteria that can now be reliably delineated [16,21,22,23]. In this review, I will first present an overview of the overall evolutionary relationships and the new classification scheme for mycobacteria that has emerged from comprehensive phylogenomic and comparative genomic approaches. The remainder of this review focuses on the results from this comparative genomic analysis which has identified >60 novel and highly-specific molecular characteristics, in the forms of conserved signature inserts and deletions (CSIs) in important proteins, that are exclusive to the M. tuberculosis complex of bacteria. The importance and usefulness of the identified CSIs as a new class of potential drug targets for development of novel drugs/compounds that will specifically target the TB-group of bacteria is discussed in the review.

2. Impact of Genomics on Clarifying the Evolutionary Relationships amongst Mycobacteria

As noted earlier, the genus Mycobacterium up to the beginning of this year contained 188 named species, which included several major human pathogens (viz. M. tuberculosis and M. leprae) as well as a large number of nonpathogenic species [10,24]. In our recent work, using available genome sequences for 150 mycobacterial species, comprehensive phylogenomics and comparative genome analyses were carried out using multiple independent approaches with the aim of understanding the evolutionary relationships among mycobacterial species [25]. Genome sequences permitted construction of phylogenetic trees for mycobacterial species based on multiple large datasets of protein sequences including 1941 core proteins representing the genus Mycobacterium, 136 core proteins specific for the phylum Actinobacteria, and 8 other highly conserved proteins that are found in all/most bacteria [25]. Phylogenetic trees based on large datasets of protein sequences are known to more accurately portray the evolutionary relationships within any given group of organisms than those based on single gene/protein sequences [19,26,27,28,29]. In all of the constructed trees, Mycobacterium species consistently grouped into five strongly supported clades at the highest level, designated as the Tuberculosis-Simiae, Terrae, Triviale, Fortuitum-Vaccae and Abscessus-Chelonae” clades. Some of these clades have also been observed in earlier phylogenetic studies [10,13,17,25]. Of these clades, the Tuberculosis-Simiae, Terrae, Triviale clades are largely comprised of slow-growing bacteria (i.e., requiring more than seven days to form colonies), while the other two clades mainly contain rapidly-growing species requiring less than seven days to form colonies [10,24]. Based on the core genome proteins of mycobacterial species, a pairwise amino acid (aa) identity between these species, which provides a measure of the overall genetic relatedness of the species, was also determined for the Mycobacterium species. The results of these analyses also confirmed that the members from each of these five clades are more similar to each other than to the members of the other respective clades [25].
In addition to these comprehensive phylogenomic studies, exhaustive comparative genomic analyses were also carried out on protein sequences from mycobacterial genomes to identify molecular signatures in the forms of CSIs and conserved signature proteins (CSPs) that are uniquely shared by either all members of the genus Mycobacterium or those exhibiting specificity for members of each of the five identified clades [16,30,31]. The importance of these molecular markers as useful tools for genetic and biochemical studies and for development of novel diagnostics and therapeutics will be discussed later. The results from these comparative genomic analyses have identified 172 molecular signatures consisting of CSIs and CSPs, which are distinctive characteristics of either all of the species from the family Mycobacteriaceae or which are specifically shared by different members of the five main clades of mycobacteria delineated by phylogenomic analyses. These molecular signatures provide strong independent evidence that the species from the five main observed clades of mycobacteria are genetically distinct from each other while also offering a reliable means for the demarcation of these groups in molecular terms. A summary diagram depicting the five main clades of mycobacteria and their interrelationships, which has emerged based on genomic analyses is presented in Figure 1 [25]. The numbers of identified molecular markers which are specific for different main clades as well various intermediate branch-points are also shown in this figure.
Based on the compelling evidence amassed from different genomic scale analyses, all of which strongly supported the existence of the five main clades within the genus Mycobacterium as depicted in Figure 1, the genus Mycobacterium has now been divided into five different genera. In the new classification scheme for the family Mycobacteriaceae, the genus name Mycobacterium is limited to only members of the Tuberculosis-Simiae clade [25]. The delimited genus Mycobacterium continues to retain all of the major human and animal pathogenic species including M. tuberculosis, M. leprae, M. bovis, etc. The species belonging to the Fortuitum-Vaccae clade, which are primarily environmental species, are now placed into a new genus Mycolicibacterium, whereas the species from the Terrae and Triviale clades, which are also nonpathogenic, except occasional association with animal hosts or human patients, are now assigned to two new genera Mycolicibacter and Mycolicibacillus, respectively [25]. Lastly, the species from the Abscessus-Chelonae, some of which are associated with lung, skin and soft tissue infections are transferred into a new genus Mycobacteroides [25].
In the new classification scheme for mycobacteria, all of the major human and animal pathogenic species are retained in the delimited genus Mycobacterium and they are separated from other genera of mycobacterial species, which are comprised of species that are either non-pathogenic or are of lesser clinical significance [25]. With the explicit division of the mycobacterial species into these distinct groups or genera, attention can now be focused on the unique genetic and molecular characteristics that differentiate the members of these different groups of microbes. Although the new classification scheme represents a significant advancement in terms of clarifying the genetic diversity that exist within the family Mycobacteriaceae, two of the main genera comprising this family i.e., Mycobacterium and Mycolicibacterium, consisting respectively of the slow-growing and fast-growing mycobacterial species, are still very large and genetically diverse. Of these, the new genus Mycobacterium contains >70 species and within it a number of different species groups viz. “Tuberculosis complex”, “Avium complex”, “Gordonae clade”, “Kansasii clade”, “Simiae clade”, and a clade of mycolactone-producing mycobacteria, are informally recognized [10,17,19,24]. Additionally, a large number of species from this genus including M. leprae, are not part of any of these clades. As the genus Mycobacterium contains some of the most significant human and animal pathogens, it is necessary to obtain a more reliable understanding of the evolutionary relationships among this group of bacteria in order to identify characteristics that differentiate the tuberculosis causing bacteria from other members of this genus.
Based on the branching patterns of species in different phylogenetic trees constructed in our earlier work [25], as well as additional phylogenomics and comparative genomics studies that we have carried out on these bacteria (to be described later), a good understanding of the evolutionary relationships among different species that comprise the new (delimited) genus Mycobacterium can now be acquired. Based on the results of these studies, at least 11 distinct species clades can be distinguished within the genus Mycobacterium based on their branching in phylogenetic trees and identified molecular signatures (Figure 2). A number of these species’ clades are similar to those indicated in earlier studies [10,24]. Of particular interest in the present context is the clade consisting of the tuberculosis-complex of species. The tuberculosis-complex consists of a tightly-clustered group of ten species (viz. M. tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium canettii, Mycobacterium caprae, Mycobacterium microti, Mycobacterium mungi, Mycobacterium orygis, Mycobacterium pinnipedii and Mycobacterium suricattae), all of which are human or animal pathogens. Genome sequences are now available for most of the species from this group. In phylogenetic trees (see Figure 2), the tuberculosis-complex of species are separated from all other mycobacteria by a long branch and the species Mycobacterium shinjukuense and Mycobacterium lacus, which are rarely pathogenic [32,33], are indicated to be their closest relatives. In view of the long-branch (i.e., genetic distance) that separates the tuberculosis-complex of species from all other bacteria, it is expected that this group of bacteria should differ significantly from all other mycobacteria in terms of their genetic and biochemical characteristics. Hence, we have carried out detailed comparisons of the sequences for different proteins from the genomes of tuberculosis-complex of species and other mycobacteria to identify novel molecular signatures such as CSIs, which are specific for the M. tuberculosis complex of species. The genetic and biochemical significance of the CSIs and a summary of the results obtained from our comparative genomics studies are described below.

3. Genetic and Biological Significance of the Conserved Signature Indels

Conserved signature indels represent an important class of molecular markers, whose discovery has been enabled by the growing availability of genome sequences [25,28,31,34,35]. Although the inserts and deletions are commonly present in gene/protein sequences, only a small subset of these indels represent CSIs that are found to be useful for the different applications indicated here [29,31]. The indels that constitute CSIs are generally of fixed lengths, present at specific positions in particular genes/proteins, and are flanked on both sides by conserved regions to ensure that they constitute reliable characteristics [25,28,31,34,35]. As the CSIs in genes/proteins sequences result from rare genetic changes, when a particular CSI is specifically shared by a phylogenetically-related group of organisms, its presence is most parsimoniously accounted by the genetic change leading to the CSI occurring in a common ancestor of the group followed by vertical inheritance of this genetic change by other group members [25,28,31,34,35]. Based upon the presence or absence of a CSI in outgroup (i.e., ancestral) species, it is also possible to infer whether a given CSI represents an insertion or a deletion. Extensive earlier work on CSIs provides evidence that both large as well as small CSIs (even a one aa insert/deletion in protein sequence) are reliable molecular markers and they both exhibit a high degree of predictive ability to be present in other members of the indicated groups for which sequence information may be lacking [16,21,28,29,35,36,37]. In view of the reliability and exclusive presence of specific CSIs in a particular group of organisms, the CSIs now provide a dependable means for the demarcation of prokaryotic taxa of different ranks (ranging from genus to phylum) in molecular terms [25,28,29,38]. Furthermore, due to the specificity of the CSIs for a given group of organisms, the genetic/molecular changes introduced by them are predicted to be important for the CSI-containing organisms and this prediction has been confirmed experimentally for several studied CSIs [39,40,41,42]. As the genotype determines and controls the phenotype, the identified CSIs also provide important genetic/biochemical tools for discovering novel properties that are important to and uniquely shared by different groups of organisms for which these CSIs are specific.

4. Conserved Signature Indels Specific for the M. tuberculosis Complex of Organisms

The results of our comparative genomic studies on mycobacterial genomes have identified 63 CSIs in important proteins that are distinctive characteristics of the tuberculosis-complex of species. Sequence information for three of these CSIs are presented in Figure 3 and Figure 4. Figure 3A shows partial sequence alignment of the protein UDP-N-acetylenolpyruvoylglucosamine reductase (MurB), which plays an essential role in the biosynthesis of peptidoglycan in both Gram-positive and Gram-negative bacteria by catalyzing the formation of UDP-N-acetyl muramic acid from UDP- N-acetyl glucosamine [43,44]. In MurB protein, a four aa insert in a highly-conserved region is uniquely found in all nine sequenced species from the tuberculosis-complex of organisms, but it is not present in any other mycobacteria or actinobacteria. The results of Himar1-based transposon mutagenesis indicate that the murB gene is essential for in vitro growth of M. tuberculosis H37Rv [45,46]. As MurB has no known eukaryotic homologues, it provides a unique antibacterial target [44].
In Figure 3B, partial sequence alignment is presented of a protein annotated as putative 3′-phosphoadenosine 5′-phosphosulfate reductase (CysH). In this protein, a seven aa insertion in a conserved region is uniquely found in all nine sequenced M. tuberculosis complex of organisms, but not in any other mycobacteria. The CysH protein catalyzes the reduction of activated sulfate into sulfite and plays an important role in the sulfate activation pathway [47]. This protein is actively expressed in macrophages during the latent phase of infection with M. tuberculosis and appears to be required for the survival of tuberculosis bacteria in the macrophages. The gene for the CysH protein is also found to be essential for in vitro growth of H37Rv strain of M. tuberculosis [45,46]. Disruption of cysH gene in M. tuberculosis has been reported to cause auxotrophy for cysteine and methionine and attenuated virulence [48]. Although a homolog of the CysH protein is present in human, it lacks the N-terminal region of the protein, where this large insertion is found. Thus, the region of the protein shown in Figure 3B is not found in humans and the large insert present in this region is a specific characteristic of the M. tuberculosis complex of organisms. We also show in Figure 4 an example a protein where a 12 aa long deletion is present in a LytR family transcriptional regulatory protein in the M. tuberculosis related organisms. Interestingly, while this large CSIs is present in all other sequenced species from the M. tuberculosis complex (eight out of nine sequenced species), it is not present in M. canettii, which branches earlier in comparison to the other species from this complex in phylogenetic trees (Figure 2). Thus, this large deletion while providing a highly-specific molecular marker for the M. tuberculosis and its close relatives serves to differentiate them from M. canettii, which is also a part of the tuberculosis-complex of species.
In addition to the CSIs shown in Figure 3 and Figure 4, our comparative genomic analyses have identified 60 other CSIs in proteins involved in many diverse functions. A summary of some characteristics of these CSIs and the proteins in which they are found is shown in Table 1. Detailed sequence information for the three CSIs shown in Figure 3 and Figure 4 and the other 60 identified CSIs are provided in Figures S1–S63. As seen from Table 1, the identified CSIs are of different lengths and they are found in proteins involved in a broad range of cellular functions including cell wall synthesis, drug and ion transport, DNA replication, transcription and repair, protein translation, biosynthesis of cofactors and coenzymes such as ubiquinone and menaquinone, and proteins playing important roles in a variety of metabolic and regulatory pathways. In addition to the proteins with annotated cellular functions, a significant proportion of proteins harboring these CSIs are conserved proteins, with no information available regarding their cellular functions. The last column in Table 1 provides information based on Himar1-transposon mutagenesis studies indicating whether the genes for these proteins were found to be essential or nonessential for the in vitro growth of M. tuberculosis [45,46].
As seen from Table 1, the genes for a significant proportion (~20%) of the proteins, where these CSIs are found have been found to be essential for the in vitro growth/function of M. tuberculosis strain H37Rv [45,46]. Besides MurB and CysH, some of the other genes/proteins containing CSIs that are essential for the growth of M. tuberculosis include, MenE protein (an acetyl coenzyme A (acyl-CoA) synthetase (ligase) playing an essential role in menaquinone biosynthesis pathway [49,50], a putative adenosine triphosphate (ATP) dependent DNA ligase (Mt-Lig) [51], polyketide synthase protein (Pks8) involved in the biosynthesis of mycolic acid [52,53], NadE (nicotinamide adenine dinucleotide (NAD+) synthetase) protein catalyzing the last step of NAD biosynthesis [54], ribonuclease E playing an important role in RNA processing and decay [55] and folylpolyglutamate synthase (FPGS or FolC) protein, involved in the conversion of folates into polyglutamates derivatives [56,57]. Folate pathway is an established target for development of antimicrobials [58] and it is of interest to note that missense mutations within the dihydropteroate binding pocket of FolC confer resistance to para-aminosalicylic acid (PAS) in clinical isolates of M. tuberculosis and confer resistance to PAS, which is an important agent in the treatment of multidrug-resistant tuberculosis [56,57,58]. Some of the other proteins containing CSIs that are essential for the growth of M. tuberculosis include propionyl-CoA carboxylase subunit beta chain playing an essential role in the catabolic pathway of odd-chain fatty acids, isoleucine, threonine, methionine, and valine [59,60], putative phosphor-sugar (glucosamine) mutase involved in glycolysis and sugar metabolism [61], DNA topoisomerase I, TOPA (omega-protein) involved in relaxation of DNA [62], indolylacetylinositol arabinosyltransferase (EmbB), involved in the biosynthesis of cell wall arabinogalactan and lipoarabinomannan and a well-established target for the drug ethambutol [63,64], and guanosine triphosphatase (GTPase) Era which has intrinsic GTPase activity and is a regulator of cell growth [65].
The CSIs in protein structures are generally located in surface-exposed loops of the proteins [39,40,66,67,68]. Structures of several proteins in which the CSIs have been identified in this work are now available for either M. tuberculosis or other organisms [69,70]. Based on the latter structures, structures of the corresponding M. tuberculosis proteins can be deduced using the homology modelling technique [71]. We have examined the structural locations of the two CSIs shown in Figure 2 in the corresponding proteins structures. For the MurB protein, its structure has been solved from M. tuberculosis (PDB ID: 5JZX) [72]. The four aa insertion in this protein which is specific for the M. tuberculosis complex of organisms (shown in red) forms a distinct lobe on the surface of the protein (Figure 5A). Using the structure of MurB protein from M. tuberculosis as a template, a homology model of this protein was also created for the Mycobacterium angelicum homolog, which lacks this CSI. The homology modelling was carried out as in our earlier work [39,66,73]. A close up of the structural comparison of the CSI-containing region for MurB from M. tuberculosis (colored in green) and M. angelicum (shown in cyan) is presented in Figure 5B. As seen, while the rest of the structures show nearly perfect overlap, the CSI in the M. tuberculosis protein (highlighted in red), extends an α-helix and forms part of a surface-exposed loop.
The structure of the CysH (3′-phosphoadenosine 5′-phosphosulfate reductase) protein from M. tuberculosis is not known. However, the structure of this protein has been solved from Pseudomonas aeruginosa (PDB ID: 2GOY) [74]. Based on the latter structure, a homology model of the CysH protein was created from M. tuberculosis. As the seven aa insertion is not present in the P. aeruginosa protein, it was modelled [39,66,73]. The structures of the modelled CysH protein from M. tuberculosis (Figure 6A), its solved structure from P. aeruginosa (Figure 6B), and a close up of the aligned structures for the CSI region from the two proteins, are shown in Figure 6. As seen from Figure 6C, the 7 aa CSI in the M. tuberculosis protein (shown in red) forms a surface-exposed loop/lobe in the protein structure (Figure 6A,C), that is lacking in the organisms not containing this CSI (Figure 6B).

5. Significance and Applications of the Tuberculosis-Complex Specific Conserved Signature Indels for Development of Novel Diagnostics and Therapeutics

Most studied CSIs exhibit a number of unique characteristics, which makes them potentially useful means for development of novel and specific diagnostic tests as well as potential targets for development of new classes of therapeutics. The usefulness of the CSIs for development of novel diagnostic tests is based on the observation that the CSIs are present in conserved regions of the genes/proteins and they exhibit a high degree of specificity for a given group of organisms [21,23,37,75,76]. Earlier work on CSIs provides compelling evidence that these molecular markers are highly specific characteristics of a given group of organisms [21,23,37,75,76]. Further, these molecular characteristics are not only specifically found in the available sequences from a given group of organisms, but that they also exhibit a high degree of predictive ability to be found in other group members for which sequence information is lacking at present [16,31,35,38]. In view of these characteristics, novel diagnostic tests for the detection of TB, based on the sequence regions harboring these CSIs, can be developed by means of different commonly used techniques e.g., polymerase chain reaction (PCR-based), real-time quantitative PCR (q-PCR-based), pyrosequencing, immunological or antibody-based methods, matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF), aptamer-based methods, as well as in silico identification of the CSI-containing organisms in genomic and metagenomic sequences. As examples of the utility of CSIs for development of novel diagnostic tests, the CSIs specific for Bacillus anthracis and Escherichia coli O157/H7 have been successfully used for the development of highly-specific diagnostic tests for these important pathogens [75,76]. Although great advancements have been made in the detection of TB and multiple diagnostic tests are available for this purpose [2,3,77,78], most of these tests are either slow, lack specificity or are costly. Given that TB is most prevalent in low to middle income countries, there is a need for developing sensitive, specific and inexpensive tests for detection of TB [9,78].
Besides their presence in conserved regions and specificity for a particular group of organisms, most studied CSIs exhibit a number of other characteristics that make them potentially useful means for development of novel therapeutics. The first of these characteristics is that the CSIs in protein sequences are predicted to play important functional roles in the organisms in which they are found [41,42,66]. It has been experimentally shown for a number of CSIs that the removal of the CSIs from studied genes/proteins, or any significant changes in their sequences by genetic means affected/inhibited the growth of the CSI-containing organisms [35,41]. These studies also demonstrated that both large as well as small CSIs (even one aa insert or deletion) play important roles in the protein’s function [35,41]. Another important characteristic of the CSIs is that nearly all studied CSIs (including the examples described here) are located in the surface-exposed loops of the proteins, located away from the protein’s active or substrate binding sites [39,40,66]. Extensive earlier work indicates that the surface loops in protein sequences play important roles in facilitating novel protein-protein or protein-ligand interactions [39,66,67,68,79]. Based on the above observations, the most plausible explanation to account for the presence and functional roles played by different CSIs that are specific for the MTB-complex of organisms is that they are involved in mediating novel interactions (viz. protein-protein or protein-ligand) of the CSI-containing proteins in the MTB-complex of organisms [39,41,66,67,68,79]. It is postulated that these interactions, which are predicted to be specific for the MTB-complex of organisms, serve to differentiate these organisms from other mycobacteria which do not contain the CSIs. Further, it is suggested that the interactions mediated by the CSIs confer selective advantage to the MTB-complex of organisms in their natural habitat [41]. The selective advantages conferred by these interactions could include the ability to obtain nutrients in a nutrient-deficient environment, protection against host defense mechanisms, or breaching of the host defenses to enable its propagation (i.e. virulence). The blocking or inhibition of these interactions is thus expected to affect the growth or virulence of the MTB-complex organisms.
The above observations indicate that the CSI-containing regions of the M. tuberculosis proteins can also serve as potential means for the screening of novel compounds, which are specifically targeted towards this group of organisms. Since the CSIs are located in surface loops of the proteins, they provide readily accessible sites for binding of small molecules. Further as noted earlier, for most of the proteins which contain the M. tuberculosis-specific CSIs, their homologs are either not found in humans, or if they are present they generally do not contain the indicated CSIs. Based on these observations, it is hypothesized that screening for small molecules, which bind specifically to the CSI-containing regions of the M. tuberculosis proteins should lead to identification of a class of compounds which will interfere with the cellular functions of the CSIs, and such compounds would likely specifically affect the growth of the MTB-complex of organisms. Mutational studies indicate that only about 20–25% of the genes/proteins containing the CSIs specific for the MTB group of organisms are essential for the in vitro growth of M. tuberculosis (Table 1) [45,46]. However, growth of the cells in vitro does not provide an accurate measure of the growth of the organism in its natural habitat, which is impacted upon by many factors [80]. As the CSIs in all of the proteins described here are specific for the MTB group of organisms, it is likely that they all play specific roles in the functioning/survival of M. tuberculosis in the host environment by enabling functional interactions with other essential proteins/components. Thus, blocking the functions of CSIs in these other “non-essential” proteins by compounds that binds specifically to them is also expected to affect the growth or virulence of M. tuberculosis and related organisms within their hosts.
To test the feasibility of using CSIs as possible drug targets, it is important to have the structural information for different M. tuberculosis proteins in which the identified CSIs are found. Although the structures of some M. tuberculosis proteins containing the CSIs are now available in the RCSB Protein Data Bank [69,70,81,82], further work on solving the structures of the proteins in which the large CSIs specific for the MTB-complex of organisms are found is necessary. Based on the structures of the proteins containing the CSIs as well as lacking the CSIs, the location of the CSI-containing regions in the protein structures can be reliably determined. High-throughput virtual screening of small molecule libraries can then be carried out to identify lead compounds [47,83,84] which bind with high affinity to only the CSI-containing regions in the proteins. Most of the work on drug discovery in the past, including structure-based drug design, has focused heavily on identification of compounds which inhibit growth by binding to the active sites of the proteins [7,8,9,50,85,86]. In contrast, identification of small molecules which inhibit cell growth or cellular function by interfering with the functions of the CSIs could represent a potentially new class of compounds that are active against the MTB-complex of organisms. Although the concept of using CSIs as possible drug-target has been suggested previously [87], the potential of these novel genetic/biochemical characteristics for new drug development remains unexplored.

6. Conclusions

Phylogenomic and comparative analyses of mycobacterial genomes sequences have provided important insights into the evolutionary relationships among this large and important group of microorganisms. The results reviewed here reveal that the TB-causing bacteria constitute a small group differing from all other mycobacteria in numerous regards. Comparative analyses of protein sequences from mycobacteria have identified 63 conserved signature indels in important proteins that are uniquely found in different members of the TB-complex of bacteria. Several characteristics of the CSIs reviewed here suggest that these novel genetic features could serve as an unexplored means for development of novel diagnostics and also as potential means for development of a new class of therapeutics specifically targeting the MTB-group of organisms.

Supplementary Materials

The following are available online at https://www.mdpi.com/2571-5135/7/4/31/s1, Figure S1: Partial sequence alignment of a conserved region of the UDP-N-acetylenolpyruvoyl-glucosamine reductase (MurB) protein showing a four amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S2: Partial sequence alignment of a conserved region of the 3′-phosphoadenosine 5′-phosphosulfate reductase CYSH protein showing a seven amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S3: Partial sequence alignment of a conserved region of the transcriptional regulator protein showing a twelve amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S4: Partial sequence alignment of a conserved region of the propionyl-CoA carboxylase betachain 5 protein showing a one amino acid deletion that is specific for most members of the “Tuberculosis” clade and is absent form most other Mycobacteriaceae; Figure S5: Partial sequence alignment of a conserved region of the O-succinylbenzoic acid-CoA ligase MenE protein showing a two amino acid insertion that is specific for members of the “Tuberculosis” clade and absent in most other Mycobacteriaceae; Figure S6: Partial sequence alignment of a conserved region of a ligase protein showing a four aminoacid insertion that is specific for members of the “Tuberculosis” clade and absent from most other Mycobacteriaceae; Figure S7: Partial sequence alignment of a conserved region of the arabinosyltransferase protein showinga three amino acid insertion that is specific for members of the “Tuberculosis” clade and absent from most other Mycobacteriaceae; Figure S8: Partial sequence alignment of a conserved region of the GTPase Era protein showing a oneamino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S9: Partial sequence alignment of a conserved region of the primosome assembly protein PriA showing a three amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S10: Partial sequence alignment of a conserved region of the phospho-sugar mutase/MRSAprotein showing a three amino acid insertion that is specific for members of the “Tuberculosis” clade and absent from most other Mycobacteriaceae; Figure S11: Partial sequence alignment of a conserved region of the polyketide synthase Pks8 protein showing a one amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S12: Partial sequence alignment of a conserved region of the Glutamine-dependent NAD(+) synthetase protein showing a one amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S13: Partial sequence alignment of a conserved region of the ribonuclease E protein showing a three amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S14: Partial sequence alignment of a conserved region of the ribonuclease E protein showing a three amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S15: Partial sequence alignment of a conserved region of the DNA topoisomerase I protein showing a three amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S16: Partial sequence alignment of a conserved region of the metal cation transporting ATPaseH protein showing a one amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S17: Partial sequence alignment of a conserved region of an acyltransferase protein showing afour amino acid insertion that is specific for members of the “Tuberculosis” clade and absent from most other Mycobacteriaceae; Figure S18: Partial sequence alignment of a conserved region of an alpha-amylase protein showing aone amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S19: Partial sequence alignment of a conserved region of the hypothetical proteinIQ48_14915 showing a three amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S20: Partial sequence alignment of a conserved region of the hypothetical proteinCAB90_01059 showing a three amino acid insertion that is specific for members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S21: Partial sequence alignment of a conserved region of the transcriptional regulator proteinshowing a one amino acid deletion that is specific for members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S22: Partial sequence alignment of a conserved region of the hypothetical protein IU12_21070 showing a four amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S23: Partial sequence alignment of a conserved region of the hypothetical protein IU14_19860 showing a two amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S24: Partial sequence alignment of a conserved region of amembrane protein showing an eight amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S25: Partial sequence alignment of a conserved region of the hypothetical protein RN11_1864 showing an eight amino acid insertion that is specific for most members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S26: Partial sequence alignment of a conserved region of a transmembrane protein showing a three amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S27: Partial sequence alignment of the hypothetical protein ERS181347_00724 showing a three amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S28: Partial sequence alignment of a conserved membrane protein showing a three amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S29: Partial sequence alignment of the fructose-bisphosphate aldolase protein showing a four amino acid insertion that is specific for members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S30: Partial sequence alignment of the fructose-bisphosphate aldolase protein showing a four amino acid insertion that is specific for members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S31: Partial sequence alignment of a conserved protein showing a three amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S32: Partial sequence alignment of the exonuclease V subunit alpha protein showing a two amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S33: Partial sequence alignment of the multidrug resistance protein EmrB showing a three amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S34: Partial sequence alignment of the Hypothetical protein ERS024213_05484 showing a one amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S35: Partial sequence alignment of the LuxR family transcriptional regulator protein showing a one amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S36: Partial sequence alignment of the polyprenyl-diphosphate synthase GrcC protein showing a three amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S37: Partial sequence alignment of the polyprenyl-diphosphate synthase GrcC protein showing a one amino acid deletion that is specific for members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S38: Partial sequence alignment of a cold-shock protein showing a two amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S39: Partial sequence alignment of a transcriptional regulator protein showing a one amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S40: Partial sequence alignment of the hypothetical protein IQ40_04435 showing a four amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S41: Partial sequence alignment of an esterase protein showing a one amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S42: Partial sequence alignment of the hypothetical protein RN11_1864 showing an eight amino acid insertion that is specific for most members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S43: Partial sequence alignment of a DEAD/DEAH box helicase protein showing a one amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S44: Partial sequence alignment of a phosphoglycerate mutase protein showing a one amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S45: Partial sequence alignment of a hypothetical protein CAB90_02390 showing a two amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S46: Partial sequence alignment of the glycerol-3-phosphate dehydrogenase protein showing a four amino acid insertion that is specific for members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S47: Partial sequence alignment of the GTP-binding protein LepA showing a three amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S48: Partial sequence alignment of the type I restriction/modification system specificity determinant HsdS protein showing a four amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S49: Partial sequence alignment of the hypothetical protein IQ38_12515 showing a two amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S50: Partial sequence alignment of the polyketide synthase protein showing a three amino acid insertion that is specific for most members of the “Tuberculosis” clade; Figure S51: Partial sequence alignment of a lipase protein showing a one amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S52: Partial sequence alignment of a secreted protein showing a one amino acid deletion that is specific for members of the “Tuberculosis” clade; Figure S53: Partial sequence alignment of the DNA polymerase IV protein showing a one amino acid deletion that is specific for most members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S54: Partial sequence alignment of an ATP-dependent DNA helicase protein showing a one amino acid deletion that is specific for members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S55: Partial sequence alignment of an ATP-dependent DNA helicase protein showing a one amino acid deletion that is specific for members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S56: Partial sequence alignment of an ATPase protein showing a one amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S57: Partial sequence alignment of a DNA glycosylase protein showing a four amino acid insertion that is specific for members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S58: Partial sequence alignment of the hypothetical protein IQ47_16905 showing a three amino acid insertion that is specific for most members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S59: Partial sequence alignment of a hydrolase protein showing a three amino acid insertion that is specific for members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S60: Partial sequence alignment of the hypothetical protein RN11_1864 showing an eight amino acid insertion that is specific for most members of the “Tuberculosis” clade and is absent from most other Mycobacteriaceae; Figure S61: Partial sequence alignment of the acyl-CoA dehydrogenase FadE27 protein showing an eight amino acid insertion that is specific for members of the “Tuberculosis” clade; Figure S62: Partial sequence alignment of an oxidoreductase protein showing an eleven amino acid deletion that is specific for most members of the “Tuberculosis” clade; Figure S63: Partial sequence alignment of the hypothetical protein IQ42_20035 showing a two amino acid deletion that is specific for most members of the “Tuberculosis” clade.

Author Contributions

Conceptualization, R.S.G.; Data acquisition: R.S.G.; Data formatting, Brian Lo, Jeen Son, Rahul Sharma, R.S.G.; Protein modeling, Rahul Sharma, R.S.G.; resources, R.S.G.; project administration, R.S.G.; funding acquisition, R.S.G.

Funding

This work was supported by Research Grant number 249924 from the Natural Science and Engineering Research Council of Canada awarded to Radhey S. Gupta. The applications of the CSIs described here are covered by a patent application.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. World Health Organization. Global Tuberculois Report 2016; World Health Organization: Geneva, Switzerland, 2017. [Google Scholar]
  2. Koch, A.; Cox, H.; Mizrahi, V. Drug-resistant tuberculosis: Challenges and opportunities for diagnosis and treatment. Curr. Opin. Pharmacol. 2018, 42, 7–15. [Google Scholar] [CrossRef] [PubMed]
  3. Lange, C.; Chesov, D.; Heyckendorf, J.; Leung, C.C.; Udwadia, Z.; Dheda, K. Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment. Respirology 2018, 23, 656–673. [Google Scholar] [CrossRef] [PubMed]
  4. Hoagland, D.T.; Liu, J.; Lee, R.B.; Lee, R.E. New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Adv. Drug Deliv. Rev. 2016, 102, 55–72. [Google Scholar] [CrossRef] [PubMed]
  5. Sharma, D.; Bisht, D.; Khan, A.U. Potential Alternative Strategy against Drug Resistant Tuberculosis: A Proteomics Prospect. Proteomes 2018, 6, 26. [Google Scholar] [CrossRef] [PubMed]
  6. Kumar, V.; Patel, S.; Jain, R. New structural classes of antituberculosis agents. Med. Res. Rev. 2018, 38, 684–740. [Google Scholar] [CrossRef] [PubMed]
  7. Evans, J.C.; Mizrahi, V. Priming the tuberculosis drug pipeline: New antimycobacterial targets and agents. Curr. Opin. Microbiol. 2018, 45, 39–46. [Google Scholar] [CrossRef] [PubMed]
  8. Campanico, A.; Moreira, R.; Lopes, F. Drug discovery in tuberculosis. New drug targets and antimycobacterial agents. Eur. J. Med. Chem. 2018, 150, 525–545. [Google Scholar] [CrossRef] [PubMed]
  9. Tiberi, S.; du, P.N.; Walzl, G.; Vjecha, M.J.; Rao, M.; Ntoumi, F.; Mfinanga, S.; Kapata, N.; Mwaba, P.; McHugh, T.D.; et al. Tuberculosis: Progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect. Dis. 2018, 18, e183–e198. [Google Scholar] [CrossRef]
  10. Magee, G.M.; Ward, A.C.; Genus, I. Mycobacterium Lehmann and Neumann 1896, 363AL. In Bergey’s Manual of Systematic Bacteriology, Vol. 5, Actinobacteria; Whitman, W., Goodfellow, M., Kampfer, P., Busse, H.-J., Trujillo, M.E., Ludwig, W., Suzuki, K., Parte, A., Eds.; Springer: New York, NY, USA, 2012; pp. 312–375. [Google Scholar]
  11. Parte, A.C. LPSN-list of prokaryotic names with standing in nomenclature. Nucl. Acids Res. 2014, 42, D613–D616. [Google Scholar] [CrossRef] [PubMed]
  12. Brzostek, A.; Pawelczyk, J.; Rumijowska-Galewicz, A.; Dziadek, B.; Dziadek, J. Mycobacterium tuberculosis is able to accumulate and utilize cholesterol. J. Bacteriol. 2009, 191, 6584–6591. [Google Scholar] [CrossRef] [PubMed]
  13. Tortoli, E. Phylogeny of the genus Mycobacterium: Many doubts, few certainties. Infect. Genet. Evol. 2012, 12, 827–831. [Google Scholar] [CrossRef] [PubMed]
  14. Falkinham, J.O. Surrounded by mycobacteria: Nontuberculous mycobacteria in the human environment. J. Appl. Microbiol. 2009, 107, 356–367. [Google Scholar] [CrossRef] [PubMed]
  15. Hartmans, S.; de Bont, J.A.M.; Stackebrandt, E. Chapter 1.1.18—The genus Mycobacterium—Nonmedical. In The Prokaryotes: Volume 3: Archaea. Bacteria: Firmicutes, Actinomycetes; Dworkin, M., Falkow, S., Rosenberg, E., Schleifer, K.H., Stackebrandt, E., Eds.; Springer New York: New York, NY, USA, 2006; pp. 889–918. [Google Scholar]
  16. Gao, B.; Gupta, R.S. Phylogenetic framework and molecular signatures for the main clades of the phylum Actinobacteria. Microbiol. Mol. Biol. Rev. 2012, 76, 66–112. [Google Scholar] [CrossRef] [PubMed]
  17. Tortoli, E.; Fedrizzi, T.; Pecorari, M.; Giacobazzi, E.; De Sanctis, V.; Bertorelli, R.; Grottola, A.; Fabio, A.; Ferretti, P.; Di Leva, F.; et al. The new phylogenesis of the genus Mycobacterium. Int. J. Mycobacteriol. 2015, 4, 77. [Google Scholar] [CrossRef]
  18. Wang, J.; McIntosh, F.; Radomski, N.; Dewar, K.; Simeone, R.; Enninga, J.; Brosch, R.; Rocha, E.P.; Veyrier, F.J.; Behr, M.A. Insights on the emergence of Mycobacterium tuberculosis from the analysis of Mycobacterium kansasii. Genome Biol. Evol. 2015, 7, 856–870. [Google Scholar] [CrossRef] [PubMed]
  19. Fedrizzi, T.; Meehan, C.J.; Grottola, A.; Giacobazzi, E.; Fregni, S.G.; Tagliazucchi, S.; Fabio, A.; Bettua, C.; Bertorelli, R.; De Sanctis, V.; et al. Genomic characterization of Nontuberculous Mycobacteria. Sci. Rep. 2017, 7, 45258. [Google Scholar] [CrossRef] [PubMed]
  20. Wee, W.Y.; Dutta, A.; Choo, S.W. Comparative genome analyses of mycobacteria give better insights into their evolution. PLoS ONE 2017, 12, e0172831. [Google Scholar] [CrossRef] [PubMed]
  21. Naushad, H.S.; Lee, B.; Gupta, R.S. Conserved signature indels and signature proteins as novel tools for understanding microbial phylogeny and systematics: Identification of molecular signatures that are specific for the phytopathogenic genera Dickeya, Pectobacterium and Brenneria. Int. J. Syst. Evol. Microbiol. 2014, 64, 366–383. [Google Scholar] [CrossRef] [PubMed]
  22. Gao, B.; Paramanathan, R.; Gupta, R.S. Signature proteins that are distinctive characteristics of Actinobacteria and their subgroups. Antonie Leeuwenhoek 2006, 90, 69–91. [Google Scholar] [CrossRef] [PubMed]
  23. Gao, B.; Gupta, R.S. Conserved indels in protein sequences that are characteristic of the phylum Actinobacteria. Int. J. Syst. Evol. Microbiol. 2005, 55, 2401–2412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Lory, S. The Family Mycobacteriaceae. In The Prokaryotes-Actinobacteria; Rosenberg, E., DeLong, E., Lory, S., Stackebrandt, E., Thompson, F., Eds.; Springer: New York, NY, USA, 2014; pp. 571–575. [Google Scholar]
  25. Gupta, R.S.; Lo, B.; Son, J. Phylogenomics and Comparative Genomic Studies Robustly Support Division of the Genus Mycobacterium into an Emended Genus Mycobacterium and Four Novel Genera. Front. Microbiol. 2018, 9, 67. [Google Scholar] [CrossRef] [PubMed]
  26. Segata, N.; Bornigen, D.; Morgan, X.C.; Huttenhower, C. PhyloPhlAn is a new method for improved phylogenetic and taxonomic placement of microbes. Nat. Commun. 2013, 4, 2304. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Wu, D.; Hugenholtz, P.; Mavromatis, K.; Pukall, R.; Dalin, E.; Ivanova, N.N.; Kunin, V.; Goodwin, L.; Wu, M.; Tindall, B.J.; et al. A phylogeny-driven genomic encyclopaedia of Bacteria and Archaea. Nature 2009, 462, 1056–1060. [Google Scholar] [CrossRef] [PubMed]
  28. Adeolu, M.; Alnajar, S.; Naushad, S.; Gupta, S. Genome-based phylogeny and taxonomy of the ‘Enterobacteriales’: Proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov. Int. J. Syst. Evol. Microbiol. 2016, 66, 5575–5599. [Google Scholar] [PubMed]
  29. Sawana, A.; Adeolu, M.; Gupta, R.S. Molecular signatures and phylogenomic analysis of the genus Burkholderia: Proposal for division of this genus into the emended genus Burkholderia containing pathogenic organisms and a new genus Paraburkholderia gen. nov. harboring environmental species. Front. Genet. 2014, 5, 429. [Google Scholar] [CrossRef] [PubMed]
  30. Gupta, R.S. Editorial: Applications of genome sequences for discovering characteristics that are unique to different groups of organisms and provide insights into evolutionary relationships. Front. Genet. 2016, 7, 27. [Google Scholar] [CrossRef] [PubMed]
  31. Gupta, R.S. Chapter 8—Identification of conserved indels that are useful for classification and evolutionary studies. In Methods in Microbiology: New Approaches to Prokaryotic Systematics; Goodfellow, M., Sutcliffe, I., Chun, J., Eds.; Academic Press: Oxford, UK, 2014; pp. 153–182. [Google Scholar]
  32. Turenne, C.; Chedore, P.; Wolfe, J.; Jamieson, F.; Broukhanski, G.; May, K.; Kabani, A. Mycobacterium lacus sp. nov., a novel slowly growing, non-chromogenic clinical isolate. Int. J. Syst. Evol. Microbiol. 2002, 52, 2135–2140. [Google Scholar] [PubMed]
  33. Saito, H.; Iwamoto, T.; Ohkusu, K.; Otsuka, Y.; Akiyama, Y.; Sato, S.; Taguchi, O.; Sueyasu, Y.; Kawabe, Y.; Fujimoto, H.; et al. Mycobacterium shinjukuense sp. nov., a slowly growing, non-chromogenic species isolated from human clinical specimens. Int. J. Syst. Evol. Microbiol. 2011, 61, 1927–1932. [Google Scholar] [CrossRef] [PubMed]
  34. Rokas, A.; Holland, P.W. Rare genomic changes as a tool for phylogenetics. Trends Ecol. Evol. 2000, 15, 454–459. [Google Scholar] [CrossRef]
  35. Gupta, R.S. Impact of genomics on the understanding of microbial evolution and classification: The importance of Darwin’s views on classification. FEMS Microbiol. Rev. 2016, 40, 520–553. [Google Scholar] [CrossRef] [PubMed]
  36. Alnajar, S.; Gupta, R.S. Phylogenomics and comparative genomic studies delineate six main clades within the family Enterobacteriaceae and support the reclassification of several polyphyletic members of the family. Infect. Genet. Evol. 2017, 54, 108–127. [Google Scholar] [CrossRef] [PubMed]
  37. Adeolu, M.; Gupta, R.S. A phylogenomic and molecular marker based proposal for the division of the genus Borrelia into two genera: The emended genus Borrelia containing only the members of the relapsing fever Borrelia, and the genus Borreliella gen. nov. containing the members of the Lyme disease Borrelia (Borrelia burgdorferi sensu lato complex). Antonie Leeuwenhoek 2014, 105, 1049–1072. [Google Scholar] [PubMed]
  38. Barbour, A.G.; Adeolu, M.; Gupta, R.S. Division of the genus Borrelia into two genera (corresponding to Lyme disease and relapsing fever groups) reflects their genetic and phenotypic distinctiveness and will lead to a better understanding of these two groups of microbes. Int. J. Syst. Evol. Microbiol. 2017, 67, 2058–2067. [Google Scholar] [PubMed]
  39. Khadka, B.; Gupta, R.S. Identification of a conserved 8 aa insert in the PIP5K protein in the Saccharomycetaceae family of fungi and the molecular dynamics simulations and structural analysis to investigate its potential functional role. Proteins 2017, 85, 1454–1467. [Google Scholar] [CrossRef] [PubMed]
  40. Alnajar, S.; Khadka, B.; Gupta, R.S. Ribonucleotide reductases from Bifidobacteria contain multiple conserved indels distinguishing them from all other organisms: In silico analysis of the possible role of a 43 aa Bifidobacteria-specific insert in the Class III RNR homolog. Front. Microbiol. 2017, 8, 1409. [Google Scholar] [CrossRef] [PubMed]
  41. Singh, B.; Gupta, R.S. Conserved inserts in the Hsp60 (GroEL) and Hsp70 (DnaK) proteins are essential for cellular growth. Mol. Genet. Genom. 2009, 281, 361–373. [Google Scholar] [CrossRef] [PubMed]
  42. Schoeffler, A.J.; May, A.P.; Berger, J.M. A domain insertion in Escherichia coli GyrB adopts a novel fold that plays a critical role in gyrase function. Nucl. Acids Res. 2010, 38, 7830–7844. [Google Scholar] [CrossRef] [PubMed]
  43. Barry, C.E.; Crick, D.C.; McNeil, M.R. Targeting the formation of the cell wall core of M. tuberculosis. Infect. Disord. Drug Targets 2007, 7, 182–202. [Google Scholar] [CrossRef] [PubMed]
  44. Moraes, G.L.; Gomes, G.C.; Monteiro de Sousa, P.R.; Alves, C.N.; Govender, T.; Kruger, H.G.; Maguire, G.E.M.; Lamichhane, G.; Lameira, J. Structural and functional features of enzymes of Mycobacterium tuberculosis peptidoglycan biosynthesis as targets for drug development. Tuberculosis 2015, 95, 95–111. [Google Scholar] [CrossRef] [PubMed]
  45. Griffin, J.E.; Gawronski, J.D.; Dejesus, M.A.; Ioerger, T.R.; Akerley, B.J.; Sassetti, C.M. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog. 2011, 7, e1002251. [Google Scholar] [CrossRef] [PubMed]
  46. Dejesus, M.A.; Gerrick, E.R.; Xu, W.; Park, S.W.; Long, J.E.; Boutte, C.C.; Rubin, E.J.; Schnappinger, D.; Ehrt, S.; Fortune, S.M.; et al. Comprehensive Essentiality Analysis of the Mycobacterium tuberculosis Genome via Saturating Transposon Mutagenesis. MBio 2017, 8. [Google Scholar] [CrossRef] [PubMed]
  47. Cosconati, S.; Hong, J.A.; Novellino, E.; Carroll, K.S.; Goodsell, D.S.; Olson, A.J. Structure-based virtual screening and biological evaluation of Mycobacterium tuberculosis adenosine 5′-phosphosulfate reductase inhibitors. J. Med. Chem. 2008, 51, 6627–6630. [Google Scholar] [CrossRef] [PubMed]
  48. Senaratne, R.H.; De Silva, A.D.; Williams, S.J.; Mougous, J.D.; Reader, J.R.; Zhang, T.; Chan, S.; Sidders, B.; Lee, D.H.; Chan, J.; et al. 5′-Adenosinephosphosulphate reductase (CysH) protects Mycobacterium tuberculosis against free radicals during chronic infection phase in mice. Mol. Microbiol. 2006, 59, 1744–1753. [Google Scholar] [CrossRef] [PubMed]
  49. Duckworth, B.P.; Nelson, K.M.; Aldrich, C.C. Adenylating enzymes in Mycobacterium tuberculosis as drug targets. Curr. Top Med. Chem. 2012, 12, 766–796. [Google Scholar] [CrossRef] [PubMed]
  50. Lu, X.; Zhang, H.; Tonge, P.J.; Tan, D.S. Mechanism-based inhibitors of MenE, an acyl-CoA synthetase involved in bacterial menaquinone biosynthesis. Bioorg. Med. Chem. Lett. 2008, 18, 5963–5966. [Google Scholar] [CrossRef] [PubMed]
  51. Pitcher, R.S.; Tonkin, L.M.; Green, A.J.; Doherty, A.J. Domain structure of a NHEJ DNA repair ligase from Mycobacterium tuberculosis. J. Mol. Biol. 2005, 351, 531–544. [Google Scholar] [CrossRef] [PubMed]
  52. Dubey, V.S.; Sirakova, T.D.; Cynamon, M.H.; Kolattukudy, P.E. Biochemical function of msl5 (pks8 plus pks17) in Mycobacterium tuberculosis H37Rv: Biosynthesis of monomethyl branched unsaturated fatty acids. J. Bacteriol. 2003, 185, 4620–4625. [Google Scholar] [CrossRef] [PubMed]
  53. Portevin, D.; Sousa-D’Auria, C.; Houssin, C.; Grimaldi, C.; Chami, M.; Daffe, M.; Guilhot, C. A polyketide synthase catalyzes the last condensation step of mycolic acid biosynthesis in mycobacteria and related organisms. Proc. Natl. Acad. Sci. USA 2004, 101, 314–319. [Google Scholar] [CrossRef] [PubMed]
  54. Bellinzoni, M.; Buroni, S.; Pasca, M.R.; Guglierame, P.; Arcesi, F.; De Rossi, E.; Riccardi, G. Glutamine amidotransferase activity of NAD+ synthetase from Mycobacterium tuberculosis depends on an amino-terminal nitrilase domain. Res. Microbiol. 2005, 156, 173–177. [Google Scholar] [CrossRef] [PubMed]
  55. Kime, L.; Vincent, H.A.; Gendoo, D.M.; Jourdan, S.S.; Fishwick, C.W.; Callaghan, A.J.; McDowall, K.J. The first small-molecule inhibitors of members of the ribonuclease E family. Sci. Rep. 2015, 5, 8028. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Chakraborty, S.; Gruber, T.; Barry, C.E.; Boshoff, H.I., III; Rhee, K.Y. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science 2013, 339, 88–91. [Google Scholar] [CrossRef] [PubMed]
  57. Zhao, F.; Wang, X.D.; Erber, L.N.; Luo, M.; Guo, A.Z.; Yang, S.S.; Gu, J.; Turman, B.J.; Gao, Y.; Li, D.; et al. Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2014, 58, 1479–1487. [Google Scholar] [CrossRef] [PubMed]
  58. Minato, Y.; Thiede, J.M.; Kordus, S.L.; McKlveen, E.J.; Turman, B.J.; Baughn, A.D. Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance. Antimicrob. Agents Chemther. 2015, 59, 5097–5106. [Google Scholar] [CrossRef] [PubMed]
  59. Rashid, A.M.; Batey, S.F.; Syson, K.; Koliwer-Brandl, H.; Miah, F.; Findlay, K.C.; Nartowski, K.P.; Kalscheuer, R.; Bornemann, S. Assembly of α-Glucan by GlgE and GlgB in Mycobacteria and Streptomycetes. Biochemistry 2016, 55, 3270–3284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  60. Lin, T.W.; Melgar, M.M.; Kurth, D.; Swamidass, S.J.; Purdon, J.; Tseng, T.; Gago, G.; Baldi, P.; Gramajo, H.; Tsai, S.-C. Structure-based inhibitor design of AccD5, an essential acyl-CoA carboxylase carboxyltransferase domain of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 2006, 103, 3072–3077. [Google Scholar] [CrossRef] [PubMed]
  61. Takayama, K.; Wang, C.; Besra, G.S. Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis. Clin. Microbiol. Rev. 2005, 18, 81–101. [Google Scholar] [CrossRef] [PubMed]
  62. Sidorenko, V.S.; Rot, M.A.; Filipenko, M.L.; Nevinsky, G.A.; Zharkov, D.O. Novel DNA glycosylases from Mycobacterium tuberculosis. Biochemistry 2008, 73, 442–450. [Google Scholar] [CrossRef] [PubMed]
  63. Huang, F.; He, Z.G. Characterization of an interplay between a Mycobacterium tuberculosis MazF homolog, Rv1495 and its sole DNA topoisomerase I. Nucl. Acids Res. 2010, 38, 8219–8230. [Google Scholar] [CrossRef] [PubMed]
  64. Goude, R.; Amin, A.G.; Chatterjee, D.; Parish, T. The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2009, 53, 4138–4146. [Google Scholar] [CrossRef] [PubMed]
  65. Alderwick, L.J.; Birch, H.L.; Mishra, A.K.; Eggeling, L.; Besra, G.S. Structure, function and biosynthesis of the Mycobacterium tuberculosis cell wall: Arabinogalactan and lipoarabinomannan assembly with a view to discovering new drug targets. Biochem. Soc. Trans. 2007, 35, 1325–1328. [Google Scholar] [CrossRef] [PubMed]
  66. Meena, L.S.; Chopra, P.; Bedwal, R.S.; Singh, Y. Cloning and characterization of GTP-binding proteins of Mycobacterium tuberculosis H37Rv. Enzyme Microb. Technol. 2008, 42, 138–144. [Google Scholar] [CrossRef] [PubMed]
  67. Hassan, F.M.N.; Gupta, R.S. Novel Sequence Features of DNA Repair Genes/Proteins from Deinococcus Species Implicated in Protection from Oxidatively Generated Damage. Genes 2018, 9, 149. [Google Scholar] [CrossRef] [PubMed]
  68. Akiva, E.; Itzhaki, Z.; Margalit, H. Built-in loops allow versatility in domain-domain interactions: Lessons from self-interacting domains. Proc. Natl. Acad. Sci. USA 2008, 105, 13292–13297. [Google Scholar] [CrossRef] [PubMed]
  69. Hormozdiari, F.; Salari, R.; Hsing, M.; Schonhuth, A.; Chan, S.K.; Sahinalp, S.C.; Cherkasov, A. The effect of insertions and deletions on wirings in protein-protein interaction networks: A large-scale study. J. Comput. Biol. 2009, 16, 159–167. [Google Scholar] [CrossRef] [PubMed]
  70. Baugh, L.; Phan, I.; Begley, D.W.; Clifton, M.C.; Armour, B.; Dranow, D.M.; Taylor, B.M.; Muruthi, M.M.; Abendroth, J.; Fairman, J.W.; et al. Increasing the structural coverage of tuberculosis drug targets. Tuberculosis 2015, 95, 142–148. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  71. Zhang, Y.; Amzel, L.M. Tuberculosis drug targets. Curr. Drug Targets 2002, 3, 131–154. [Google Scholar] [CrossRef] [PubMed]
  72. Sali, A.; Blundell, T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234, 779–815. [Google Scholar] [CrossRef] [PubMed]
  73. Chartron, J.; Carroll, K.S.; Shiau, C.; Gao, H.; Leary, J.A.; Bertozzi, C.R.; Stout, C.D. Substrate recognition, protein dynamics, and iron-sulfur cluster in Pseudomonas aeruginosa adenosine 5′-phosphosulfate reductase. J. Mol. Biol. 2006, 364, 152–169. [Google Scholar] [CrossRef] [PubMed]
  74. Eniyan, K.; Dharavath, S.; Vijayan, R.; Bajpai, U.; Gourinath, S. Crystal structure of UDP-N-acetylglucosamine-enolpyruvate reductase (MurB) from Mycobacterium tuberculosis. Biochim. Biophys. Acta 2018, 1866, 397–406. [Google Scholar] [CrossRef] [PubMed]
  75. Gupta, R.S.; Nanda, A.; Khadka, B. Novel molecular, structural and evolutionary characteristics of the phosphoketolases from bifidobacteria and Coriobacteriales. PLoS ONE 2017, 12, e0172176. [Google Scholar] [CrossRef] [PubMed]
  76. Ahmod, N.Z.; Gupta, R.S.; Shah, H.N. Identification of a Bacillus anthracis specific indel in the yeaC gene and development of a rapid pyrosequencing assay for distinguishing B. anthracis from the B. cereus group. J. Microbiol. Methods 2011, 87, 278–285. [Google Scholar] [CrossRef] [PubMed]
  77. Wong, S.Y.; Paschos, A.; Gupta, R.S.; Schellhorn, H.E. Insertion/deletion-based approach for the detection of Escherichia coli O157:H7 in freshwater environments. Environ. Sci. Technol. 2014, 48, 11462–11470. [Google Scholar] [CrossRef] [PubMed]
  78. Eddabra, R.; Ait, B.H. Rapid molecular assays for detection of tuberculosis. Pneumonia 2018, 10, 4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  79. Walzl, G.; McNerney, R.; du, P.N.; Bates, M.; McHugh, T.D.; Chegou, N.N.; Zumla, A. Tuberculosis: Advances and challenges in development of new diagnostics and biomarkers. Lancet Infe. Dis. 2018, 18, e199–e210. [Google Scholar] [CrossRef]
  80. Lamichhane, G.; Zignol, M.; Blades, N.J.; Geiman, D.E.; Dougherty, A.; Grosset, J.; Broman, K.W.; Bishai, W.R. A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 2003, 100, 7213–7218. [Google Scholar] [CrossRef] [PubMed]
  81. Keiser, T.L.; Purdy, G.E. Killing Mycobacterium tuberculosis In Vitro: What Model Systems Can Teach Us. Microbiol. Spectr. 2017, 5. [Google Scholar] [CrossRef] [PubMed]
  82. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucl. Acids Res. 2000, 28, 235–242. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  83. Brotz-Oesterhelt, H.; Sass, P. Postgenomic strategies in antibacterial drug discovery. Future Microbiol. 2010, 5, 1553–1579. [Google Scholar] [CrossRef] [PubMed]
  84. Sharma, K.; Chopra, P.; Singh, Y. Recent advances towards identification of new drug targets for Mycobacterium tuberculosis. Expert Opin. Ther. Targets 2004, 8, 79–93. [Google Scholar] [CrossRef] [PubMed]
  85. Kalyaanamoorthy, S.; Chen, Y.P. Structure-based drug design to augment hit discovery. Drug Discov. Today 2011, 16, 831–839. [Google Scholar] [CrossRef] [PubMed]
  86. Singh, V.; Mizrahi, V. Identification and validation of novel drug targets in Mycobacterium tuberculosis. Drug Discov. Today 2017, 22, 503–509. [Google Scholar] [CrossRef] [PubMed]
  87. Nandan, D.; Lopez, M.; Ban, F.; Huang, M.; Li, Y.; Reiner, N.E.; Cherkasov, A. Indel-based targeting of essential proteins in human pathogens that have close host orthologue(s): Discovery of selective inhibitors for Leishmania donovani elongation factor-1α. Proteins 2007, 67, 53–64. [Google Scholar] [CrossRef] [PubMed]
High throughput 07 00031 g001 550
Figure 1. A compressed tree showing the main clades of mycobacteria observed in phylogenomic trees and molecular markers that have been identified for different clades. The tree shown is based on 1941 core proteins from the genomes of 150 Mycobacteriaceae species [25]. The terms CSIs and CSPs refer to conserved signature indels and conserved signature proteins, respectively, which are specific for the species from the observed clades. Comprehensive analyses of genome sequences have led to division of the family Mycobacteriaceae (genus Mycobacterium) into five different genera as indicated here [25].
Figure 1. A compressed tree showing the main clades of mycobacteria observed in phylogenomic trees and molecular markers that have been identified for different clades. The tree shown is based on 1941 core proteins from the genomes of 150 Mycobacteriaceae species [25]. The terms CSIs and CSPs refer to conserved signature indels and conserved signature proteins, respectively, which are specific for the species from the observed clades. Comprehensive analyses of genome sequences have led to division of the family Mycobacteriaceae (genus Mycobacterium) into five different genera as indicated here [25].
High throughput 07 00031 g001
High throughput 07 00031 g002 550
Figure 2. A compressed phylogenetic tree showing the main clades observed within the delimited genus Mycobacterium in a phylogenetic tree. The tree shown is based on 136 proteins commonly shared by members of the phylum Actinobacteria. The tree was constructed as described in earlier work [25] and the main species groupings observed are collapsed, except those from the M. tuberculosis-related group of bacteria. The group of species that is commonly referred to as the tuberculosis-complex is marked. All of the CSIs described in this work are specific for the tuberculosis-complex of bacteria.
Figure 2. A compressed phylogenetic tree showing the main clades observed within the delimited genus Mycobacterium in a phylogenetic tree. The tree shown is based on 136 proteins commonly shared by members of the phylum Actinobacteria. The tree was constructed as described in earlier work [25] and the main species groupings observed are collapsed, except those from the M. tuberculosis-related group of bacteria. The group of species that is commonly referred to as the tuberculosis-complex is marked. All of the CSIs described in this work are specific for the tuberculosis-complex of bacteria.
High throughput 07 00031 g002
High throughput 07 00031 g003 550
Figure 3. Partial sequence alignments of the proteins (A) UDP-N-acetylenolpyruvoyl-glucosamine reductase (MurB) and (B) 3′-phosphoadenosine 5′-phosphosulfate reductase (CysH), containing conserved inserts of four amino acid (aa) and seven aa (boxed), respectively, which are uniquely found in the tuberculosis-complex of bacteria. The numbers 9/9 indicate that there are 9 sequences available from the Tuberculosis-complex of bacteria and all 9 of them contain these CSIs. However, these CSIs are lacking in the homologs from all other mycobacteria as well as other examined bacteria. The homologs of these proteins, or the CSI-containing regions of these proteins, are not found in human. The dashes (-) in different sequence alignments show identity with the aa present on the top line. Mutational studies indicate that both these proteins are essential for the growth of M. tuberculosis [45,46].
Figure 3. Partial sequence alignments of the proteins (A) UDP-N-acetylenolpyruvoyl-glucosamine reductase (MurB) and (B) 3′-phosphoadenosine 5′-phosphosulfate reductase (CysH), containing conserved inserts of four amino acid (aa) and seven aa (boxed), respectively, which are uniquely found in the tuberculosis-complex of bacteria. The numbers 9/9 indicate that there are 9 sequences available from the Tuberculosis-complex of bacteria and all 9 of them contain these CSIs. However, these CSIs are lacking in the homologs from all other mycobacteria as well as other examined bacteria. The homologs of these proteins, or the CSI-containing regions of these proteins, are not found in human. The dashes (-) in different sequence alignments show identity with the aa present on the top line. Mutational studies indicate that both these proteins are essential for the growth of M. tuberculosis [45,46].
High throughput 07 00031 g003
High throughput 07 00031 g004 550
Figure 4. Partial sequence alignment of a LytR family transcriptional regulatory protein showing a 12 aa long deletion in a conserved region. This deletion is uniquely present in all other M. tuberculosis complex of organisms except Mycobacterium canettii, which branches earlier in comparison to the other species from this group (Figure 2). The dashes (-) indicate identity with the aa present on the top line.
Figure 4. Partial sequence alignment of a LytR family transcriptional regulatory protein showing a 12 aa long deletion in a conserved region. This deletion is uniquely present in all other M. tuberculosis complex of organisms except Mycobacterium canettii, which branches earlier in comparison to the other species from this group (Figure 2). The dashes (-) indicate identity with the aa present on the top line.
High throughput 07 00031 g004
High throughput 07 00031 g005 550
Figure 5. Structural localization of the CSI in the MurB protein. (A) Resolved structure of the UDP-N-acetylenolpyruvoylglucosamine reductase (MurB) protein from M. tuberculosis (PDB ID: 5JZX) [72]. The four aa insertion is highlighted in red. (B) A close up of the CSI region from M. tuberculosis proteins colored in green, and a homology model of the same protein from Mycobacterium angelicum, shown in cyan.
Figure 5. Structural localization of the CSI in the MurB protein. (A) Resolved structure of the UDP-N-acetylenolpyruvoylglucosamine reductase (MurB) protein from M. tuberculosis (PDB ID: 5JZX) [72]. The four aa insertion is highlighted in red. (B) A close up of the CSI region from M. tuberculosis proteins colored in green, and a homology model of the same protein from Mycobacterium angelicum, shown in cyan.
High throughput 07 00031 g005
High throughput 07 00031 g006 550
Figure 6. Structural location of the CSI in the CysH protein. (A) Homology model of the 3′-phosphoadenosine 5′-phosphosulfate reductase CysH protein from M. tuberculosis (based on PDB ID: 2GOY). The seven aa insertion is highlighted in red and boxed. (B) Resolved structure of the CysH protein from Pseudomonas aeruginosa (PDB ID: 2GOY). The region homologous to the insert is boxed. (C) A close-up of the CSI region in the aligned structures of the two proteins, with CSIs marked in red.
Figure 6. Structural location of the CSI in the CysH protein. (A) Homology model of the 3′-phosphoadenosine 5′-phosphosulfate reductase CysH protein from M. tuberculosis (based on PDB ID: 2GOY). The seven aa insertion is highlighted in red and boxed. (B) Resolved structure of the CysH protein from Pseudomonas aeruginosa (PDB ID: 2GOY). The region homologous to the insert is boxed. (C) A close-up of the CSI region in the aligned structures of the two proteins, with CSIs marked in red.
High throughput 07 00031 g006
Table
Table 1. Summary of conserved signature indels (CSIs) that are specific for the tuberculosis complex.
Table 1. Summary of conserved signature indels (CSIs) that are specific for the tuberculosis complex.
NameGene Number
(M. tuberculosis H37Rv)		Figure NumberIns/DelLocationMutational Results #
putative UDP-N-acetylenolpyruvoyl-glucosamine reductase (MurB)Rv0482Figure 3A, Figure S14aa Ins249–298Essential
putative 3′-phosphoadenosine 5′-phosphosulfate reductase (CysH) (PAPS reductase, thioredoxin dep)Rv2392Figure 3B, Figure S27aa Ins17–71Essential (growth defect)
transcriptional regulator, LytR familyRv3840Figure 4, Figure S312aa Del50–87Non-essential
putative propionyl-CoA carboxylase beta chain 5 ACCD5 (PCCASE)Rv3280Figure S41aa Del172–220Essential
O-succinylbenzoic acid-CoA ligase MenE *Rv0542cFigure S52aa Ins41–95Essential
ligase *Rv3712Figure S64aa Ins180–234Essential
arabinosyltransferase EmbB *Rv3795Figure S73aa Ins747–795Essential
GTPase EraRv2364cFigure S81aa Ins225–283Essential (growth defect)
primosome assembly protein PriARv1402Figure S93aa Ins609–655Essential
putative phospho-sugar mutase/MRSA homolog *Rv3441cFigure S103aa Ins43–102Essential
polyketide synthase Pks8Rv1662Figure S111aa Del539–586Non-essential
Glutamine-dependent NAD(+) synthetaseRv2438cFigure S121aa Del584–641Essential
ribonuclease ERv2444cFigure S133aa Ins219–269Essential
putative folylpolyglutamate synthase protein (FolC)Rv2447cFigure S143aa Ins111–170Essential
DNA topoisomerase I TOPA (omega-protein)Rv3646cFigure S153aa Ins392–440Essential
metal cation transporting ATPase HRv0425cFigure S161aa Del963–1014Non-essential
Acyltransferase *Rv1565cFigure S174aa Ins162–220Non-essential
α-amylaseRv2471Figure S181aa Del428–477Non-essential
hypothetical protein IQ48_14915, partialRv0897cFigure S193aa Ins257–306Non-essential
hypothetical protein CAB90_01059 *Rv0938Figure S203aa Ins422–469Non-essential
transcriptional regulator *Rv1186cFigure S211aa Del406–457Non-essential
hypothetical protein IU12_21070Rv0008cFigure S224aa Ins10–59Non-essential
hypothetical protein IU14_19860Rv0029Figure S232aa Del194–250Non-essential
membrane proteinRv0051Figure S248aa Ins470–522Non-essential
hypothetical protein RN11_1864 *Rv0094cFigure S258aa Ins18–67Non-essential
transmembrane proteinRv0188Figure S263aa Del18–55Non-essential
hypothetical protein ERS181347_00724Rv0209Figure S273aa Ins195–242Non-essential
conserved membrane proteinRv0210Figure S283aa Ins10–59Non-essential
fructose-bisphosphate aldolase *Rv0365cFigure S294aa Ins144–193Non-essential
anti-sigma K factorRv0444cFigure S301aa Ins147–206Non-essential
conserved protein of uncharacterised function % 2C possibly exportedRv0518Figure S313aa Ins36–84Non-essential
exonuclease V subunit αRv0629cFigure S322aa Del109–159Non-essential
multidrug resistance protein EmrBRv0783cFigure S333aa Del320–366Non-essential
Hypothetical protein ERS024213_05484Rv0789cFigure S341aa Del39–91Non-essential
LuxR family transcriptional regulatorRVBD_0890cFigure S351aa Del290–328Non-essential
polyprenyl-diphosphate synthase GrcCRv0989cFigure S363aa Del205–251Non-essential
polyprenyl-diphosphate synthase GrcCRv0989cFigure S371aa Del94–141Non-essential
cold-shock proteinRv1253Figure S382aa Del220–275Non-essential
transcriptional regulatorRv1358Figure S391aa Ins94–152Non-essential
hypothetical protein IQ40_04435Rv1359Figure S404aa Ins150–208Non-essential
esteraseRv1497Figure S411aa Ins296–344Non-essential
hypothetical protein RN11_1864 *Rv0094cFigure S428aa Ins165–213Non-essential
DEAD/DEAH box helicaseRv2092cFigure S431aa Del579–624Non-essential
phosphoglycerate mutaseRv2135cFigure S441aa Del01–48Non-essential
hypothetical protein CAB90_02390Rv2137cFigure S452aa Ins10–54Non-essential
putative glycerol-3-phosphate dehydrogenase *Rv2249cFigure S464aa Ins333–380Non-essential
GTP-binding protein LepARv2404cFigure S473aa Ins298–355Non-essential
type I restriction/modification system specificity determinant HsdSRv2761cFigure S484aa Ins10–58Non-essential
hypothetical protein IQ38_12515, partialRv2762cFigure S492aa Del42–81Non-essential
polyketide synthase *Rv2940cFigure S503aa Ins1311–1359Non-essential
lipaseRv2970cFigure S511aa Ins170–225Non-essential
secreted proteinRv3054cFigure S521aa Del13–61Non-essential
DNA polymerase IV *Rv3056Figure S531aa Del208–254Non-essential
ATP-dependent DNA helicase *Rv3202cFigure S541aa Del378–426Non-essential
membrane proteinRv3207cFigure S551aa Ins207–256Non-essential
ATPaseRv3220cFigure S561aa Ins215–269Non-essential
DNA glycosylase *Rv3297Figure S574aa Ins80–132Non-essential
hypothetical protein IQ47_16905, partial *Rv3394cFigure S583aa Ins78–123Non-essential
hydrolase *Rv3400Figure S593aa Ins141–186Non-essential
hypothetical protein RN11_1864 *Rv0094cFigure S608aa Ins19–68Non-essential
acyl-CoA dehydrogenase FadE27Rv3505Figure S618aa Ins162–211Non-essential
oxidoreductase *Rv3742cFigure S6211aa Del25–65Non-essential
hypothetical protein IQ42_20035 *Rv3912Figure S632aa Del113–159Non-essential
# Inferences whether the genes encoding different proteins are essential or not required for in vitro growth of M. tuberculosis H37Rv are based on the results from Himar1 based transposon mutagenesis reported in literature [45,46], * Some exceptions are seen for these CSIs.

Share and Cite

MDPI and ACS Style

Gupta, R.S. Impact of Genomics on Clarifying the Evolutionary Relationships amongst Mycobacteria: Identification of Molecular Signatures Specific for the Tuberculosis-Complex of Bacteria with Potential Applications for Novel Diagnostics and Therapeutics. High-Throughput 2018, 7, 31. https://doi.org/10.3390/ht7040031

AMA Style

Gupta RS. Impact of Genomics on Clarifying the Evolutionary Relationships amongst Mycobacteria: Identification of Molecular Signatures Specific for the Tuberculosis-Complex of Bacteria with Potential Applications for Novel Diagnostics and Therapeutics. High-Throughput. 2018; 7(4):31. https://doi.org/10.3390/ht7040031

Chicago/Turabian Style

Gupta, Radhey S. 2018. "Impact of Genomics on Clarifying the Evolutionary Relationships amongst Mycobacteria: Identification of Molecular Signatures Specific for the Tuberculosis-Complex of Bacteria with Potential Applications for Novel Diagnostics and Therapeutics" High-Throughput 7, no. 4: 31. https://doi.org/10.3390/ht7040031

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop